Literature DB >> 32878853

Desperate times, desperate measures: successful use of chemotherapy in treatment of haemophagocytic lymphohistiocytosis (HLH) due to disseminated histoplasmosis.

Sunny Rajendra Kumar Singh1, Kannan Thanikachalam2, Vijayalakshmi Donthireddy2.   

Abstract

We describe a case of haemophagocytic lymphohistiocytosis (HLH) secondary to disseminated histoplasmosis, which was treated with chemotherapy in addition to standard antifungal therapy. While HLH in the setting of infections is very well described, its treatment in this setting is controversial, with some physicians treating only the underlying infection, whereas others using immune suppression in addition to antimicrobials. To the best of our knowledge, this is the first report documenting the successful treatment of an adult patient with HLH due to disseminated histoplasmosis using etoposide chemotherapy after initial antifungal therapy failed to show improvement. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  biological agents; haematology (incl blood transfusion); hepatitis other; immunology; infectious diseases

Mesh:

Substances:

Year:  2020        PMID: 32878853      PMCID: PMC7470499          DOI: 10.1136/bcr-2020-235144

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

Review 2.  How I treat hemophagocytic lymphohistiocytosis in the adult patient.

Authors:  Alison M Schram; Nancy Berliner
Journal:  Blood       Date:  2015-03-10       Impact factor: 22.113

3.  Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.

Authors:  D Salmon-Ceron; F Tubach; O Lortholary; O Chosidow; S Bretagne; N Nicolas; E Cuillerier; B Fautrel; C Michelet; J Morel; X Puéchal; D Wendling; M Lemann; P Ravaud; X Mariette
Journal:  Ann Rheum Dis       Date:  2010-12-21       Impact factor: 19.103

4.  Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis.

Authors:  Zaher K Otrock; Charles S Eby
Journal:  Am J Hematol       Date:  2015-01-16       Impact factor: 10.047

5.  Reactivation of latent granulomatous infections by infliximab.

Authors:  Robert S Wallis; Michael Broder; John Wong; Albert Lee; Lalima Hoq
Journal:  Clin Infect Dis       Date:  2005-08-01       Impact factor: 9.079

Review 6.  Hemophagocytic Syndrome in the Setting of AIDS and Disseminated Histoplasmosis: Case Report and a Review of Literature.

Authors:  Anup Subedee; Nicholas Van Sickels
Journal:  J Int Assoc Provid AIDS Care       Date:  2015-02-10

7.  Safe usage of anakinra and dexamethasone to treat refractory hemophagocytic lymphohistiocytosis secondary to acute disseminated histoplasmosis in a patient with HIV/AIDS.

Authors:  Anthony J Ocon; Birju D Bhatt; Cynthia Miller; Ruben A Peredo
Journal:  BMJ Case Rep       Date:  2017-10-04

8.  Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients.

Authors:  Sébastien Rivière; Lionel Galicier; Paul Coppo; Christophe Marzac; Cedric Aumont; Olivier Lambotte; Laurence Fardet
Journal:  Am J Med       Date:  2014-05-14       Impact factor: 4.965

Review 9.  Infections associated with haemophagocytic syndrome.

Authors:  Nadine G Rouphael; Naasha J Talati; Camille Vaughan; Kelly Cunningham; Roger Moreira; Carolyn Gould
Journal:  Lancet Infect Dis       Date:  2007-12       Impact factor: 25.071

10.  Hemophagocytic Lymphohistiocytosis and Progressive Disseminated Histoplasmosis.

Authors:  Kenice Ferguson-Paul; Spencer Mangum; Ashley Porter; Vasiliki Leventaki; Patrick Campbell; Joshua Wolf
Journal:  Emerg Infect Dis       Date:  2016-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.